Literature DB >> 6357058

Synthetic peptide immunogens as vaccines.

T M Shinnick, J G Sutcliffe, N Green, R A Lerner.   

Abstract

Synthetic peptide immunogens have been shown to elicit antibodies that can react with full-length proteins containing that peptide. Such antibodies are directed against a specific region of the protein chosen in advance by the investigator and so have a predetermined specificity. In basic research, these antibodies are useful in identifying the protein product of an open reading frame, localizing the gene product to particular cells or subcellular organelles, identifying the enzymatic function of a protein product, following the fate of particular regions of a product through protein maturation processes, analyzing the expression of exons following DNA rearrangements and RNA splicing, and purifying the protein by immunoaffinity chromatography techniques. In medicine, such antibodies may provide reagents for passive vaccination, antitoxin therapy, and targeted immunotherapy of neoplasia. The peptides themselves may be used as synthetic vaccines. The immediate future of the synthetic peptide immunogen in medicine is clear--the promise demonstrated in the laboratory must be reduced to safe application in the hospital. Two barriers to this are the selection of precisely the best peptide and the selection of the proper adjuvant. Currently, a brute force approach is utilized to find the best peptide for eliciting the desired antibodies. This is clearly a problem when the pathogenic organism is assayable only in man. Possibly, by combining studies on the antigenicity of the pathogenic organism with an analysis of naturally occurring variants that alter its immunogenicity, peptide selection will be made easier. Also, since the adjuvants and carriers used in the laboratory are in general too harsh for widespread use in humans and animals, much work needs to be done to find suitable adjuvants and carriers. Nonetheless, now that the major conceptual hurdle to synthetic peptide vaccines has been cleared (that is, it is not necessary to reproduce conformation exactly), it should be relatively straightforward to solve the remaining problems.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357058     DOI: 10.1146/annurev.mi.37.100183.002233

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  29 in total

1.  Rat muscle acylphosphatase: purification, amino sequence, and immunological characterization.

Authors:  A Berti; E Tremori; L Pazzagli; D Degl'Innocenti; G Camici; G Cappugi; G Manao; G Ramponi
Journal:  J Protein Chem       Date:  1991-02

2.  Monoclonal antibodies: a potentially powerful tool in the diagnosis and treatment of infectious diseases.

Authors:  G Spira; R R Pollock; A Bargellesi; M D Scharff
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

3.  Determination of royal jelly freshness by ELISA with a highly specific anti-apalbumin 1, major royal jelly protein 1 antibody.

Authors:  Li-rong Shen; Yi-ran Wang; Liang Zhai; Wen-xiu Zhou; Liang-liang Tan; Mei-lu Li; Dan-dan Liu; Fa Xiao
Journal:  J Zhejiang Univ Sci B       Date:  2015-02       Impact factor: 3.066

4.  Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

Authors:  F Delpeyroux; E Van Wezel; B Blondel; R Crainic
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4.

Authors:  K Midthun; Y Hoshino; A Z Kapikian; R M Chanock
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

6.  New dimensions in vaccinology: A new insight.

Authors:  D Tomar; V Chattree; V Tripathi; A A Khan; A R Bakshi; D N Rao
Journal:  Indian J Clin Biochem       Date:  2005-01

7.  Synthetic peptides corresponding to protective epitopes of Escherichia coli digalactoside-binding pilin prevent infection in a murine pyelonephritis model.

Authors:  M A Schmidt; P O'Hanley; D Lark; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

8.  Inhibition of pertussis toxin binding to model receptors by antipeptide antibodies directed at an antigenic domain of the S2 subunit.

Authors:  M A Schmidt; W Schmidt
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

Review 9.  Idiotypic vaccines and infectious diseases.

Authors:  J R Hiernaux
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

10.  Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: adaptability to various vehicles and pyrogenicity.

Authors:  M Tsujimoto; S Kotani; F Kinoshita; S Kanoh; T Shiba; S Kusumoto
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.